DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Grn163l is an investigational drug.
There have been 14 clinical trials for Grn163l. The most recent clinical trial was a Phase 2 trial, which was initiated on November 1st 2010.
The most common disease conditions in clinical trials are Breast Neoplasms, Neoplasms, Plasma Cell, and Multiple Myeloma. The leading clinical trial sponsors are Geron Corporation, National Cancer Institute (NCI), and Breast Cancer Research Foundation.
There are eight US patents protecting this investigational drug and fifty-one international patents.
Recent Clinical Trials for Grn163l
|Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors||National Cancer Institute (NCI)||Phase 2|
|Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors||Children's Oncology Group||Phase 2|
|Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors||National Cancer Institute (NCI)||Phase 2|
Top disease conditions for Grn163l
Top clinical trial sponsors for Grn163l
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Grn163l||See Pricing||Method for identification of sensitivity of a patient to telomerase inhibition therapy||Geron Corporation (Menlo Park, CA)||See Pricing|
|Grn163l||See Pricing||Combined telomerase inhibitor and gemcitabine for the treatment of cancer||Geron Corporation (Menlo Park, CA)||See Pricing|
|Grn163l||See Pricing||Cancer treatment by combined inhibition of proteasome and telomerase activities||Geron Corporation (Menlo Park, CA) Memorial Sloan-Kettering Cancer Center (New York, NY)||See Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|